NO20034322D0 - Behandling av demens og neurodegenerative sykdommer med intermediate doserav LHRH-antagonister - Google Patents

Behandling av demens og neurodegenerative sykdommer med intermediate doserav LHRH-antagonister

Info

Publication number
NO20034322D0
NO20034322D0 NO20034322A NO20034322A NO20034322D0 NO 20034322 D0 NO20034322 D0 NO 20034322D0 NO 20034322 A NO20034322 A NO 20034322A NO 20034322 A NO20034322 A NO 20034322A NO 20034322 D0 NO20034322 D0 NO 20034322D0
Authority
NO
Norway
Prior art keywords
dementia
treatment
neurodegenerative diseases
lhrh antagonists
intermediate doses
Prior art date
Application number
NO20034322A
Other languages
English (en)
Norwegian (no)
Other versions
NO20034322L (no
Inventor
Juergen Engel
Rainer Voegeli
Original Assignee
Zentaris Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zentaris Gmbh filed Critical Zentaris Gmbh
Publication of NO20034322L publication Critical patent/NO20034322L/no
Publication of NO20034322D0 publication Critical patent/NO20034322D0/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/09—Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
NO20034322A 2001-04-30 2003-09-26 Behandling av demens og neurodegenerative sykdommer med intermediate doserav LHRH-antagonister NO20034322D0 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US28743401P 2001-04-30 2001-04-30
PCT/EP2002/004677 WO2002102401A1 (en) 2001-04-30 2002-04-27 Treatment of dementia and neurodegenerative diseases with intermediate doses of lhrh antagonists

Publications (2)

Publication Number Publication Date
NO20034322L NO20034322L (no) 2003-09-26
NO20034322D0 true NO20034322D0 (no) 2003-09-26

Family

ID=23102886

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20034322A NO20034322D0 (no) 2001-04-30 2003-09-26 Behandling av demens og neurodegenerative sykdommer med intermediate doserav LHRH-antagonister

Country Status (27)

Country Link
US (1) US7288517B2 (enExample)
EP (1) EP1392348B1 (enExample)
JP (1) JP2004529207A (enExample)
KR (1) KR20040000446A (enExample)
CN (1) CN1317030C (enExample)
AT (1) ATE400287T1 (enExample)
AU (1) AU2002310788B2 (enExample)
BG (1) BG108339A (enExample)
BR (1) BR0209290A (enExample)
CA (1) CA2444876A1 (enExample)
CZ (1) CZ20033167A3 (enExample)
DE (1) DE60227507D1 (enExample)
DK (1) DK1392348T3 (enExample)
ES (1) ES2307760T3 (enExample)
HU (1) HUP0400067A2 (enExample)
IL (1) IL156777A0 (enExample)
MX (1) MXPA03008666A (enExample)
NO (1) NO20034322D0 (enExample)
NZ (1) NZ544417A (enExample)
PL (1) PL362319A1 (enExample)
PT (1) PT1392348E (enExample)
RU (1) RU2319501C2 (enExample)
SI (1) SI1392348T1 (enExample)
SK (1) SK14512003A3 (enExample)
UA (1) UA80679C2 (enExample)
WO (1) WO2002102401A1 (enExample)
ZA (1) ZA200305326B (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6828415B2 (en) * 1993-02-19 2004-12-07 Zentaris Gmbh Oligopeptide lyophilisate, their preparation and use
US20020077327A1 (en) * 1999-09-23 2002-06-20 Neurocrine Biosciences, Inc. Gonadotropin-releasing hormone receptor antagonists and methods relating thereto
AU7102201A (en) * 2000-07-05 2002-01-14 Yamanouchi Pharma Co Ltd Propane-1,3-dione derivatives
DE10137174A1 (de) * 2001-07-31 2003-02-13 Zentaris Ag Verwendung von LHRH-Antagonisten in nichtkastrierenden Dosen zur Verbesserung der T-Zellen-vermittelten Immunität
EP1752452A4 (en) * 2004-06-04 2010-07-14 Astellas Pharma Inc DERIVATIVE OF PROPANE-1, 3-DIONE OR ITS SALT
US20080171736A1 (en) * 2004-12-23 2008-07-17 Gregory Christopher W Treatment of Alzheimer's Disease and Mild Cognitive impairment using GnRH-I analogs and one or more of acetylcholinesterase inhibitors and NMDA receptor antagonists
WO2006071274A2 (en) * 2004-12-23 2006-07-06 Voyager Pharmaceutical Corporation Leuprolide acetate and acetylcholinesterase inhibitors or nmda receptor antagonists for the treatment of alzheimer’s disease
RU2404973C2 (ru) * 2005-03-31 2010-11-27 Астеллас Фарма Инк. Производное соединение пропан-1,3-диона или его соль
US8642598B2 (en) * 2006-10-21 2014-02-04 Abbvie Inc. Heterocyclic compounds and their use as glycogen synthase kinase 3 inhibitors
WO2009039983A2 (en) * 2007-09-11 2009-04-02 Mondobiotech Laboratories Ag Use of a peptide as a therapeutic agent
WO2009043441A1 (en) * 2007-09-11 2009-04-09 Mondobiotech Laboratories Ag D-ala-gln-octadecyl ester as a therapeutic agent
EP2095818A1 (en) * 2008-02-29 2009-09-02 AEterna Zentaris GmbH Use of LHRH antagonists at non-castrating doses
EP2307040B1 (en) * 2008-05-29 2015-09-09 Isr Immune System Regulation Ab Use of gnrh and sex hormones for treating viral disease, in particular hiv/aids
CN103119035B (zh) 2010-09-27 2015-09-30 雅培股份有限两合公司 杂环化合物和它们作为糖原合成酶激酶-3抑制剂的用途
US9090592B2 (en) 2010-12-30 2015-07-28 AbbVie Deutschland GmbH & Co. KG Heterocyclic compounds and their use as glycogen synthase kinase-3 inhibitors
EP3560555A1 (en) * 2018-04-26 2019-10-30 LifeArc A composition for treating one or more estrogen related diseases
WO2025155903A1 (en) * 2024-01-19 2025-07-24 Temple University-Of The Commonwealth System Of Higher Education Compositions of antioxidant translation modulators for treating neurodegenerative disorders

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3135743A (en) 1960-06-29 1964-06-02 Sterling Drug Inc Steroido[2. 3-d]isoxazoles and preparation thereof
JP2000511532A (ja) 1996-05-20 2000-09-05 メルク エンド カンパニー インコーポレーテッド 性腺刺激ホルモン放出ホルモンのアンタゴニスト
DE19911771B4 (de) 1999-03-17 2006-03-30 Zentaris Gmbh LHRH-Antagonist, Verfahren zu seiner Herstellung und seiner Verwendung
WO2000069859A1 (en) 1999-05-14 2000-11-23 Neurocrine Biosciences, Inc. Imidazo- and pyrrolo[1,2-a]pyrimid-4-ones as gonadotropin-releasing hormone receptor antagonists
CA2309395A1 (en) 1999-06-04 2000-12-04 Richard Lloyd Bowen Methods for preventing and treating alzheimer's disease
ES2249302T3 (es) * 1999-10-15 2006-04-01 Neurocrine Biosciences, Inc. Antagonistas del receptor de la hormona liberadora de gonadotropina y sus metodos de uso relacionados.
WO2001078780A1 (en) 2000-04-13 2001-10-25 Takeda Chemical Industries, Ltd. Preventives/remedies for alzheimer's disease
AU7102201A (en) 2000-07-05 2002-01-14 Yamanouchi Pharma Co Ltd Propane-1,3-dione derivatives

Also Published As

Publication number Publication date
EP1392348B1 (en) 2008-07-09
KR20040000446A (ko) 2004-01-03
CN1317030C (zh) 2007-05-23
CA2444876A1 (en) 2002-12-27
ATE400287T1 (de) 2008-07-15
IL156777A0 (en) 2004-02-08
JP2004529207A (ja) 2004-09-24
EP1392348A1 (en) 2004-03-03
NO20034322L (no) 2003-09-26
ZA200305326B (en) 2003-07-30
HK1072000A1 (en) 2005-08-12
MXPA03008666A (es) 2004-10-15
ES2307760T3 (es) 2008-12-01
RU2319501C2 (ru) 2008-03-20
CN1575185A (zh) 2005-02-02
WO2002102401A1 (en) 2002-12-27
CZ20033167A3 (cs) 2004-08-18
DE60227507D1 (de) 2008-08-21
RU2003134949A (ru) 2005-02-10
US7288517B2 (en) 2007-10-30
US20020177556A1 (en) 2002-11-28
SK14512003A3 (sk) 2004-08-03
AU2002310788B2 (en) 2007-04-05
UA80679C2 (en) 2007-10-25
PL362319A1 (en) 2004-10-18
NZ544417A (en) 2008-03-28
SI1392348T1 (sl) 2008-12-31
DK1392348T3 (da) 2008-09-29
HUP0400067A2 (hu) 2004-04-28
BR0209290A (pt) 2004-07-13
BG108339A (bg) 2004-11-30
PT1392348E (pt) 2008-09-09

Similar Documents

Publication Publication Date Title
NO20034322L (no) Behandling av demens og neurodegenerative sykdommer med intermediate doserav LHRH-antagonister
EA200201247A1 (ru) Соединения для лечения болезни альцгеймера
TR200001608T2 (tr) Amiloidojenik hastalığın önlenmesi ve tedavisi
NO20022531D0 (no) Vaksine for forebyggelse og behandling av Alzheimer og amyloidrelaterte sykdommer
LU92854I2 (fr) Combinaison de rilpivirine ou une forme thérapeutique équivalente qui en dérive telle que protégé par le brevet de base, tel qu'un sel pharmaceutiquement acceptable de rilpivirine, incluant le sel chlorhydrate de rilpivirine, et ténofovir, en particulier le fumarate de ténofovir disoproxil
LTPA2015001I1 (lt) Tioflavino dariniai ir jų panaudojimas Alzhaimerio ligos diagnostikai ir terapijai
GB0223040D0 (en) Therapeutic compounds
DE60221665D1 (de) Impfstoff zur verhütung und behanldung von alzheimer-demenz und von amyloid-bezogenen krankheiten
WO2002002518A3 (en) Compounds to treat alzheimer's disease
WO2002002520A8 (en) Compounds to treat alzheimer's disease
DE69533174D1 (de) Pyridopyrimidinone, chinoline und anellierte n-heterozyklen als bradykinin-antagonisten
EA200400352A1 (ru) Органолептически приемлемые распадающиеся во рту композиции
EA200301223A1 (ru) Лекарственные формы окскарбазепина
DE60144514D1 (de) Verwendung von il-18 inhibitoren
EA200800880A1 (ru) Комбинация росиглитазона и донепезила, предназначенная для улучшения когнитивной функции
NO20000771L (no) Anvendelse av fankinon for behandling av Alzheimers sykdom
AU2003248660A8 (en) Treatment of vascular dysfunction and alzheimer's disease
MX9707642A (es) Uso de 2-oxoindol-1-carboxamidas 3-sustituidas y sus sales de base farmaceuticamente aceptables para preparar composiciones para el tratamiento y prevencion de la enfermedad de alzheimer en mamiferos, incluyendo a humanos.
DE60028928D1 (de) Verwendung von angiotensin ii rezeptorantagonisten zur behandlung von akutem myokardischen infarkt
BR0000486A (pt) Antagonistas do neuropeptìdeo y
NO20053341D0 (no) Hindring og behandling av Alzheimers sykdom.
SE0002353D0 (sv) New use
MXPA03008406A (es) Nuevas composiciones de medicamentos sobre la base de agentes anticolinergicos y agentes antagonistas de endotelina.
DK0836853T3 (da) Anvendelse af bradykinin-antagonister til fremstilling af lægemidler til behandling og forebyggelse af Alzheimers sygdom
YU9099A (en) Use of 2-phenyl-1,2-benzisoselenazol-3(2h)-one for producting a pharmaceutical preparation for treatment of the alzheimer's disease

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application